

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Bulevirtide for treating chronic hepatitis D [ID3732]

Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • MYR Pharmaceuticals (bulevirtide) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addenbrookes Liver Transplant Association • African Health Policy Network (AHPN) • Black Health Agency for Equality • British Liver Trust • Compass UK • GMFA - The Gay Men's Health Charity • Hepatitis B Positive Trust • HIV i-Base • Liver4Life • NAM publications • National AIDS Trust • Release • South Asian Health Foundation • Specialised Healthcare Alliance • Terrence Higgins Trust • The Hepatitis B Foundation UK • UK Harm Reduction Alliance • We Are With You <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Clinical Biochemists – Microbiology Section • Association of Surgeons of Great Britain and Ireland • British Association for Sexual Health and HIV • British Association for the Study of the Liver • British Blood Transfusion Society • British Committee for Standards in Haematology 	<p><u>General</u></p> <ul style="list-style-type: none"> • Alcohol and Drugs Action (ADA) • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hepatitis Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Scottish Society of Gastroenterology • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Roche (Peginterferon alfa-2a) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Cochrane Infectious Diseases Group • Foundation for Liver Research • MRC Clinical Trials Unit • National Institute for Health Research • UCL Centre for Sexual Health & HIV Research

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Geriatrics Society • British HIV Association (BHIVA) • British Infection Association • British Society for Haematology • British Society of Gastroenterology • British Viral Hepatitis Group • Hepatitis Nurse Specialist Forum • Infection Prevention Society • Microbiology Society • National Association of Primary Care (NAPC) • NHS Blood and Transplant • Primary Care Society for Gastroenterology • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons of England • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Clinical Virology Network • UK Harm Reduction Alliance <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Barking & Dagenham CCG • NHS England • NHS Northumberland CCG • Welsh Government 	<ul style="list-style-type: none"> • UK National Screening Committee <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.